Eicosanoids

Veralox Therapeutics Appoints Michael Hanna As Chief Medical Officer

Retrieved on: 
Wednesday, June 23, 2021
Eicosanoids, Enzymes, Lipoxygenase, Chemistry, Branches of biology

FREDERICK, Md., June 23, 2021 /PRNewswire/ --Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the appointment of Michael S. Hanna, MD, FACC, as chief medical officer.

Key Points: 
  • FREDERICK, Md., June 23, 2021 /PRNewswire/ --Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the appointment of Michael S. Hanna, MD, FACC, as chief medical officer.
  • "We are very pleased that Michael Hanna is joining the Veralox team at an important time in our growth as we continue progression of our first clinical trial with VLX-1005, a first-in-class small molecule inhibitor of 12-lipoxygenase in development for the treatment of heparin-induced thrombocytopenia (HIT)," said Jeffrey W. Strovel, PhD, chief executive officer of Veralox Therapeutics.
  • He is author on more than 60 peer-reviewed publications and has been guest lecturer at many leading medical meetings and conferences around the world.
  • VERALOX Therapeutics Inc. ( https://veralox.com/ ) is developing first-in-class therapeutics that target the underlying pathologies of diseases with unmet medical needs based on advanced understanding of the role of 12-lipoxygenase (12-LOX) in the onset and development of many serious diseases and conditions.

HempFusion Completes Inflammatory Markers Pilot Trial, Releases White Paper

Retrieved on: 
Thursday, March 25, 2021
Research, Fitness & Nutrition, Tobacco, Specialty, Food, Beverage, Alternative medicine, Health, Cosmetics, Retail, Science, Health sciences, Health, Branches of biology, Eicosanoids, Thromboxane, Clinical trial, Inflammation

Results of the pilot study have shown potential promise in the area of inflammatory markers and possible effects on exaggerated inflammation.

Key Points: 
  • Results of the pilot study have shown potential promise in the area of inflammatory markers and possible effects on exaggerated inflammation.
  • I was pleased to see a CBD product show such a significant reduction of thromboxane in this pilot trial.
  • HempFusion continues to focus on research & development, pilot studies, and clinical trials, to advance the science of CBD.
  • In particular and without limitation, this news release contains forward-looking statements relating to the publication of the white paper and the Companys plans, focus and objectives.

Specialized Pro-Resolving Mediators (SPMs) Shown to Resolve Inflammation and Improve Infection Clearance

Retrieved on: 
Wednesday, January 13, 2021
Branches of biology, Immunology, Eicosanoids, Animal physiology, Human physiology, Inflammation, Specialized pro-resolving mediators, Resolvin

Specialized pro-resolving mediators, or SPMs, control the inflammation resolution process, explained study co-author Dr. Andrew G. Swick, Chief Scientific Officer at Life Extension.

Key Points: 
  • Specialized pro-resolving mediators, or SPMs, control the inflammation resolution process, explained study co-author Dr. Andrew G. Swick, Chief Scientific Officer at Life Extension.
  • This is important because chronic inflammation is best managed by both limiting inflammation in the first place and promoting the resolution of that inflammation after it occurs.
  • SPMs have shown tremendous potential for treating infectious diseases and lung conditions, Dr. Shayna Sandhaus, co-author of the article, explained.
  • Administering SPMs in preclinical studies has led to infection clearance, resolution of lung inflammation, and improved survival rates.

Akari Therapeutics to Participate in Two January Virtual Investor Conferences

Retrieved on: 
Wednesday, January 6, 2021
Eicosanoids, Communication, Forward-looking statement, Leukotriene B4, Leukotriene, Private Securities Litigation Reform Act

Akari's lead drug candidate, nomacopan (formerly known as Coversin), is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity.

Key Points: 
  • Akari's lead drug candidate, nomacopan (formerly known as Coversin), is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity.
  • Certain statements in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
  • You should not place undue reliance upon the Companys forward looking statements.
  • We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.

Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of Uveitis and Retinal Disease

Retrieved on: 
Thursday, December 3, 2020
Medical specialties, Clinical medicine, Medicine, Eicosanoids, T helper 17 cell, Immunology, Uveitis, Leukotriene B4, Intravitreal administration, T cell, Dexamethasone

Key findings were that IVT administration of the long-acting engineered form of nomacopan that only binds to LTB4 was at least as effective as the steroid dexamethasone in reducing retinal inflammation.

Key Points: 
  • Key findings were that IVT administration of the long-acting engineered form of nomacopan that only binds to LTB4 was at least as effective as the steroid dexamethasone in reducing retinal inflammation.
  • Nomacopan significantly decreased proliferation, differentiation and infiltration of Th17 and Th1/17 effector CD43 T cells and reduced activated macrophage cell populations, each of which is reported as having a causative role in uveitis disease pathology.
  • Intravitreal LTB4 and C5a was elevated in response to EAU and the level rose from initiation until the disease peaked at Day 21.
  • Leukotriene B4 (LTB4) and its receptor in Experimental Autoimmune Uveitis (EAU) and in human retinal tissues: clinical severity and LTB4-dependence of retinal Th17 cells.

Akari Therapeutics to Participate in Two September Virtual Investor Conferences

Retrieved on: 
Thursday, September 10, 2020
Medical specialties, Organ systems, Eicosanoids, Autoimmune diseases, Clinical medicine, Acquired hemolytic anemia, Histopathology, Thrombotic microangiopathy, Pemphigoid, Bullous pemphigoid, Leukotriene B4, TMA

Investors interested in arranging a virtual meeting with the Company's management during either conference should contact the respective conference coordinator.

Key Points: 
  • Investors interested in arranging a virtual meeting with the Company's management during either conference should contact the respective conference coordinator.
  • Akari's lead drug candidate, nomacopan (formerly known as Coversin), is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity.
  • Nomacopan is currently being clinically evaluated in four target indications: bullous pemphigoid (BP), thrombotic microangiopathy (TMA), atopic keratoconjunctivitis (AKC), and COVID-19 pneumonia.
  • We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.

Akari Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Recent Clinical Progress

Retrieved on: 
Tuesday, September 1, 2020
Eicosanoids, Leukotriene B4

NEW YORK and LONDON, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced financial results for the second quarter ended June 30, 2020, as well as recent clinical progress.

Key Points: 
  • NEW YORK and LONDON, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced financial results for the second quarter ended June 30, 2020, as well as recent clinical progress.
  • In Brazil, patient recruitment has been completed for a proof of principle clinical study; potential progression into a follow-on randomized study is expected in early fourth quarter 2020.
  • This follows positive topline results from Akaris fully recruited Phase II study of nomacopan in BP patients previously announced in May 2020.
  • As a result of the COVID-19 pandemic, site initiations were delayed and Akari expects enrollment to now commence in the fourth quarter of 2020.

Novateur Ventures explores new strategy to reduce the hyperinflammatory response caused by COVID-19

Retrieved on: 
Thursday, August 6, 2020
Organic compounds, Medical specialties, Chemical compounds, Immunology, Eicosanoids, Leukotriene antagonists, Leukotriene, Polyenes, Zileuton, Montelukast, Coronavirus disease, Inflammation

VANCOUVER, British Columbia, Aug. 06, 2020 (GLOBE NEWSWIRE) -- A novel strategy has been developed by Novateur Ventures , which provides new hope in battle against COVID-19.

Key Points: 
  • VANCOUVER, British Columbia, Aug. 06, 2020 (GLOBE NEWSWIRE) -- A novel strategy has been developed by Novateur Ventures , which provides new hope in battle against COVID-19.
  • The study titled A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 by Targeting Leukotrienes was published in Frontiers in Pharmacology , a leading peer-reviewed journal.
  • The strategy co-authored by Ali Ardakani, Founder & Managing Director at Novateur Ventures, and Dr. Colin D. Funk (Queen's University, Kingston) analyzes lipid mediators, known as leukotrienes, as the cause for hyperinflammatory response manifested in severe COVID-19 cases.
  • The proposed zileuton/montelukast combination could readily be added in this setting, with the goal to switch off the hyper-inflammatory response.

Unicity International Issued A Landmark Patent For Its Novel Approach To Increasing The Body's Resolvin Production

Retrieved on: 
Friday, July 24, 2020
Nutrition, Molecules, Fatty acids, Chemistry, Articles, Eicosanoids, Lipids, Resolvin, Omega-3 fatty acid, Fat, Patent

OREM, Utah, July 24, 2020 /PRNewswire/ --Unicity International, a leader in metabolic health solutions, has been issued a US patent for an innovative process in its OmegaLife-3 Resolv supplement: US Pat.

Key Points: 
  • OREM, Utah, July 24, 2020 /PRNewswire/ --Unicity International, a leader in metabolic health solutions, has been issued a US patent for an innovative process in its OmegaLife-3 Resolv supplement: US Pat.
  • Unicity International R&D scientists submitted the patent application on April 12, 2017.
  • Resolvins are compounds derived from omega-3 fatty acids, and they are widely known for their ability to promote healthy inflammation levels.
  • "The patent process is not an easy onewe know this as we have patented other Unicity products and formulations," says Unicity Chief Operating Officer Dan Hughes.

Akari Therapeutics Reports First Quarter 2020 Financial Results and Highlights Recent Clinical Progress

Retrieved on: 
Friday, May 29, 2020
Eicosanoids, Leukotriene B4

NEW YORK and LONDON, May 29, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced financial results for the first quarter ended March 31, 2020, as well as recent clinical progress.

Key Points: 
  • NEW YORK and LONDON, May 29, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced financial results for the first quarter ended March 31, 2020, as well as recent clinical progress.
  • Akari continues to make progress driving its anti-inflammatory programs forward, including the recent announcement of positive topline results from our Phase II BP study in May.
  • Akaris lead programs are in BP, AKC, and HSCT-TMA where clinical data with nomacopan has shown rapid and sustained clinical improvement in patients.
  • In May 2020, Akari announced positive topline results from its fully recruited Phase II study of nomacopan in BP patients.